-
1 Comment
Zhejiang Starry Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 14.4% below its 200 day moving average.
From a valuation standpoint, the stock is 6.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10.3.
Zhejiang Starry Pharmaceutical Co., Ltd's total revenue sank by 7.3% to $324M since the same quarter in the previous year.
Its net income has increased by 32.6% to $59M since the same quarter in the previous year.
Finally, its free cash flow fell by 2409.2% to $-66M since the same quarter in the previous year.
Based on the above factors, Zhejiang Starry Pharmaceutical Co., Ltd gets an overall score of 1/5.
| ISIN | CNE1000026N8 |
|---|---|
| Exchange | SHG |
| CurrencyCode | CNY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 5B |
|---|---|
| PE Ratio | None |
| Target Price | 10.65 |
| Dividend Yield | 1.4% |
| Beta | 0.65 |
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadobenate dimeglumine injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, ioversol, iopromide, iomeprol, gadobenate dimeglumine, gadobutrol, and other products; quinolone APIs and intermediates, such as levofloxacin and levofloxacin hydrochloride; and CMO/CDMO APIs and intermediates, including CIBA, OPAA, 3N, ILC, JSQ, iodine, aza, and loxoprofen sodium. It also engages in technology promotion and application; investment; physical education; and wholesale activities. Zhejiang Starry Pharmaceutical Co.,Ltd. was incorporated in 1997 and is headquartered in Taizhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603520.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
